COMPASS Pathways to Attend Upcoming Evercore ISI HealthCONx Conference

COMPASS Pathways to Attend Upcoming Evercore ISI HealthCONx Conference

COMPAS course

COMPAS route

LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx conference at 9:15 a.m. ET on November 30, 2022.

A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS site. The replay of the webcast will be accessible for 30 days after the event. For more information, please visit

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our goal is to improve the lives of those who suffer from mental health problems and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated Breakthrough Therapy by the US Food and Drug Administration (FDA) and received Innovative Licensing and Access Pathway (ILAP) designation in the UK for Treatment Resistant Depression (TRD). We have completed a Phase 2b clinical trial of psilocybin therapy for TRD at 22 sites in Europe and North America and are preparing to begin a Phase 3 program by the end of 2022. This trial of phase 2b was the largest randomized, controlled, double-blind clinical trial of psilocybin therapy ever conducted, and our primary data showed a statistically significant (p<0.001) and clinically relevant improvement in symptom severity depression after three weeks for patients who received a single high dose of psilocybin COMP360 with psychological support. We are also conducting Phase 2 clinical trials of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental well-being.

Availability of other COMPASS Pathways information
Investors and others should note that we communicate with our investors and the public through our website (, our investor relations website ( and on social media (LinkedIn) , including but not limited to investor presentations and investor information sheets, filings with the United States Securities and Exchange Commission, press releases, public conference calls and webcasts. The information we post on these channels and websites could be considered material information. Accordingly, we encourage investors, the media and others interested in us to regularly review the information posted on these channels, including the Investor Relations website. This list of channels may be updated from time to time on our Investor Relations website and may include additional social media channels. The content of our website or these channels, or any other website accessible from our website or these channels, should not be taken as incorporated by reference in any filing under the Securities Act of 1933.


Media: Amy Lawrence,, +44 7813 777 919
Investors: Stephen Schultz,, +1 401 290 7324

#COMPASS #Pathways #Attend #Upcoming #Evercore #ISI #HealthCONx #Conference

Leave a Comment

Your email address will not be published. Required fields are marked *